A six-point prognostic model: node-positive primary (1 point), CEA >200 ng/mL or CA19-9 >200 U/mL (1 point), KRAS/NRAS/BRAF-mutated tumor (1 point) extrahepatic disease (1 point), mTBS between 5 and 11 (1 point) and mTBS more than 12 (2 points). Here, CEACAM5 is linked to neoplasm.